Fig. 2.

Monthly Trials Data for “Screen No Trial Available” Percentages. In Fig. 2, it is seen that the percentages recorded for “Screen No Trial Available” events had no significant trend. Fluctuations in rates were most likely due to physician trends in referral patterns or changes in patient load, rather than true effects due to the impacts of opening trials. The denominator used was total patients who were “screen negative” events for each month, including cancer patients for whom there was no trial available and patients who were found to have benign disease presentations.